Together, these findings suggest that ASO 3074B can enhance the functional activity of rare CFTR mutants when combined with ETI treatment and may represent a promising therapeutic option for CF patients carrying these ultra-rare mutations. The gene discussed is CFTR; the disease is cystic fibrosis.